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Background: Recent reductions in malaria in sub-Saharan Africa have been associated with increased coverage
with long-lasting insecticidal nets (LLINs). Pyrethroids are currently the only insecticide class used for treating nets,
and the rapid increase in resistance to pyrethroids in vector mosquitoes may jeopardise future vector control. Nets
containing a novel combination of permethrin, a pyrethroid, and pyriproxyfen, an insect juvenile hormone mimic,
(PPF-LLIN) may enhance malaria control, as well as reducing the spread of pyrethroid-resistant mosquitoes. This trial
will determine whether PPF-LLINs provide incremental protection against malaria over current best practice of LLINs
and prompt treatment in an area with pyrethroid-resistant vectors.
Methods: A 2 armed cluster-randomised controlled trial will be conducted in Burkina Faso to assess whether
PPF-LLIN (containing 2% permethrin and 1% pyriproxyfen w/w) provide better protection against clinical malaria in
children than 2% permethrin-treated LLINs. Study subjects will be recruited and provided with LLINs at the start of the
study. The LLINs will be exchanged for PPF-LLIN by cluster in a step-wedge fashion so 3 months before the end of the
2 year trial all participants will have a PPF-LLIN. The primary endpoint will be clinical malaria incidence measured by
passive case detection in a cohort of children, aged 6 months to 5 years. Anaemia and parasite prevalence will also be
measured in children during cross-sectional surveys. Exposure to malaria parasites will be assessed using light traps
followed by identification of common vector species and their sporozoite infection rates. Safety evaluation will include
recording of adverse events and pregnancy outcomes. The main endpoint analysis will include adjusting for distance
between village clusters with different types of nets, as the impact of PPF-LLIN is likely to increase as larger areas are
dominated by PPF-LLIN, reducing the spill over of mosquitoes from villages with LLINs.
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Discussion: The step-wedge design is to measure the impact of an incrementally delivered environmental intervention
where we expect the degree of control to be improved as more people use PPF-LLIN over a larger area. Trial findings
will help inform policy makers on the effectiveness of PPF-LLIN nets for malaria control in areas of pyrethroid resistance.
Trial registration: ISRCTN21853394 – AvecNet, registered on 3 April 2013.
Keywords: Insecticide resistance management, Malaria control, Insecticide-treated bed net, Pyrethroid, Pyriproxyfen,
Insect juvenile hormone mimic, Clinical malaria, Entomological inoculation rate, Cluster randomized controlled trialBackground
Enormous progress has been made in the control of
malaria in sub-Saharan Africa over the past decade [1,2].
A significant part of this achievement has resulted from
a large-scale increase of long-lasting insecticidal net
(LLIN) distribution and indoor residual spray campaigns,
both interventions being extremely successful tools for
malaria control [3,4]. Nonetheless, the future success of
these programmes is threatened by the development of
insecticide resistance in the vectors [5]. Resistance is of
particular concern since, until now, bed nets can only be
treated with pyrethroids because of their rapid knock-
down activity, high mosquito mortality ability and ex-
tremely low toxicity to humans [6,7]. Thus, although an
intact bed net is protective as a physical barrier [8,9],
tolerance of malaria vectors to pyrethroids would dra-
matically reduce the protection afforded by LLINs.
In order to increase the effectiveness of LLINs, net treat-
ments are being developed where nets are treated with a pyr-
ethroid in combination with another active ingredient, such
as pyriproxyfen [10,11]. Pyriproxyfen is an insect juvenile hor-
mone mimic that is recommended for vector control by the
World Health Organization (WHO) because it is effective at
extremely low concentrations, is safe for people [6], and has
no cross resistance with other classes of insecticide used for
vector control. Its primary effect is to prevent metamorphosis
of pupae into adults. In addition, it can sterilise adult mosqui-
toes, or at least reduce their fecundity and longevity
[10,12-15]. Pyriproxyfen has good residual activity in fresh
water, with studies on mosquito control showing that it can
be effective for 5 to 9 months after initial treatment [16,17].
Polyethylene nets treated with a combination of permeth-
rin and pyriproxyfen (PPF-LLIN; trade name Olyset Duo
(Sumitomo Chemical, Japan),) have been shown to induce
higher mortality and reduce blood feeding of pyrethroid-
resistant Anopheles gambiae s.s. than permethrin-only
LLINs (Olyset) in experimental hut trials [11]. However, no
controlled study demonstrates that PPF-LLIN will provide
incremental protection against malaria beyond the current
best practice of LLIN and prompt treatment in a controlled
trial. Building on current best practice, the present trial aims
to measure the incremental impact of PPF-LLIN on clinical
malaria in communities using LLINs alone and having ac-
cess to rapid treatment. To achieve this we will conduct acluster randomised controlled trial in rural villages to the
south-east of Banfora town in Burkina Faso, a country
where malaria is relatively stable [18]. Mosquitoes in this
area are currently increasing in resistance to pyrethroids.
In 2010 in Tiefora, located at the edge of our trial zone,
there was resistance to 1,1,1-trichloro-2,2-di(4-chlorophenyl)
ethane (DDT) (12% mortality), permethrin (48% mortality)
and deltamethrin (39% mortality) (S N'Fale, personnel
communication).
Here we describe the proposed trial design and the
methodology used. Although some of the outcome mea-
surements and methods in this protocol are based on a
previous vector control trial conducted in West Africa
[19], the nature of the intervention and setting have led
to many novel features.
Study objectives
Clinical
Primary objective To assess whether PPF-LLIN provide
added protection against clinical malaria in children
compared with pyrethroid-only LLINs over 2 malaria
transmission seasons of follow-up.
Secondary objectives
Efficacy
 To assess whether PPF-LLIN provide added protection
compared to LLINs against anaemia and/or parasite
prevalence in children.
 To assess and compare the prevalence of
microscopy-confirmed gametocyte carriers in the
LLIN group versus the PPF-LLIN group.Safety
 To assess whether PPF-LLIN have a safety profile
comparable with conventional LLINs in the trial
population.
Entomological
Primary objective To assess whether PPF-LLIN reduce
the entomological inoculation rate (EIR) of mosquitoes
collected inside houses compared to LLINs.
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 To assess whether PPF-LLIN reduce pyrethroid
resistance in the vector population.
 To assess the impact of PPF-LLIN on Anopheles
gambiae and Anopheles funestus on egg production
and the survival of the larvae that emerge from
these eggs.
Methods/Design
Study area and participant eligibility
The study site is situated south of the road from Banfora
and Sideradougou (10° 56’ 00” N, 004° 46’ 00” W) and is
approximately 1,250 km2, bisected by a river in a north-
south axis. It is an area of West Sudanian savannah and
the climate consists of a rainy season from May to
October with little rain in other months. This defines
the seasonal malaria transmission with most malaria epi-
sodes experienced during or immediately following the
rainy season. The study area has 6 health centres and
every village is affiliated to only 1 health centre. A base-
line demographic survey conducted in July 2013 enu-
merated 63,903 individuals living in 93 villages, with
most people living in small rural villages in houses made
with mud or cement walls and thatched or metal roofs.
The study’s field station is based at Banfora town which
is the main town in the district. This study is in an area
of cotton growing since 1968 with both the S and M
forms of An. gambiae s.s. [20].
Each village or groups of neighbouring villages with
more than 50 children aged 6 months to 5 years old will
be invited to join the study, and will constitute a single
cluster. Following local custom, sensitisation will start by
discussions with community elders and then with repre-
sentatives of the whole study community in order to ex-
plain the nature and requirements of the study. Village
level permission will then be sought after sensitization
meetings attended by village community leaders and
health staff at the health centres; attendees’ names and
village of residence will be documented. Witnessed writ-
ten consent will also be sought from each net recipient,
before net donation and exchange (Additional file 1).
During these procedures it will be made clear that
people will be able to leave the study at any time but
that their original net will not be returned.
A cohort of children will be enrolled to assess the im-
pact of the intervention on malaria. A minimum of 40
children per cluster (range 40 to 75), depending on clus-
ter size, will be randomly selected, stratified by age and
invited to participate in the clinical and travel/residence
surveys and passive case detection (PCD). The random
sample will be stratified by age so that approximately
equal numbers of children below and above 36 months
will be invited into the study. This was done in casethere were marked differences in clinical malaria associ-
ated with the different age groups and to ensure balance
between the 2 study arms. No distinctions in the sam-
pling scheme will be made regarding gender, ethnic
group, medical condition or physical health. Children
will only be included on the condition that their carers/
parents give witnessed informed written consent. Assur-
ance will also be sought from carers/parents that they
expect that the child will remain resident in their village
during the transmission season and will not be sent
away. If informed consent is not provided for a ran-
domly selected child then replacement children will be
randomly selected from those remaining in the village.
The impact of the intervention on the density of mal-
aria vectors and their infection rate with malaria sporo-
zoites will be measured in each village cluster. In each
cluster 6 compounds will be selected randomly, from
those that have consented to join the study and have at
least 4 houses. In each household a room with a single
adult male sleeper will be selected if the room owner/
sleeper provides witnessed, verbal consent.
Design
A cluster-randomised controlled trial design will be used
since: i) LLINs are a community-level intervention; and
ii) the village cluster is a suitable unit for randomization
since they represent a discrete spatial cluster. At the out-
set of the study, all households will be provided with
new LLINs at the rate of 1.1 nets for every 2 people in
their household; this will approximate 1 for every sleep-
ing place. Each month for the next 4 months after LLIN
donation, residents in 5 randomly selected village clus-
ters will be asked to exchange their LLINs for PPF-
LLIN. Stratified, random sampling will be used to ensure
that by the end of year 1 (September 2014) there will be
a similar number of residents with and without PPF-
LLINs affiliated to each health centre. Every month from
June to September in 2015, an additional 5 village clus-
ters will be provided with PPF-LLIN, thus by the end of
September 2015 all clusters will have PPF-LLIN (Fig-
ure 1). It is important that within the study area there
are no villages that are not enrolled in the study in order
for the PPF-LLIN to have maximum impact on larval
populations and minimize the spill-over of mosquitoes
from villages without these nets. LLINs and PPF-LLIN
will be the same shape, size and colour and marked with
a unique code number, so that the investigators are
blinded to the identity of the net (apart from those field
assistants distributing nets).
Clinical malaria will be recorded by study nurses using
PCD methods during the rainy seasons in years 1 and 2.
Parasites will be detected by rapid diagnostic tests
(RDTs) and thick smears will be stained for confirmation
Figure 1 Step-wedge design for roll-out of bednets. Permethrin-treated nets were given to all clusters in May 2014, followed by pyriproxyfen
& permethrin treated nets (red) being rolled-out to different clusters in 2014 and 2015.
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low government guidelines.
The study cohort will be surveyed for malaria indices
(parasite prevalence, anaemia and spleen rate) at the be-
ginning and end of both transmission seasons to gener-
ate data for the secondary endpoints. Where possible, at
each malaria survey except the first, an average of 50
children from each village cluster who have not been en-
rolled in the cohort but are of a similar age will also be
surveyed for these malaria indices. This additional group
of children may better reflect the Plasmodium falcip-
arum parasite rate in the population than children in the
PCD cohort. Baseline data from the cohort will be used
to compare the village clusters before the interventions,
and the cohort from each village cluster provides its
own baseline data before net exchange to PPF-LLIN. In
addition, we will request anonymized medical records
from the 6 health facilities located in the valley and use
these to document clinical malaria in children aged 6
months to 5 years living in villages outside the study
area. These children represent a further control group
which can be used to track temporal changes in malaria
incidence during the study period. If malaria declines in
the study area in year 2, but not outside, we can be
confident that the decline is due to the intervention, ra-
ther than confounding factors such as low rainfall. The
end-of-season survey data will also be used to attempt
to define a P. falciparum parasitaemia cut-off giving
optimum sensitivity and specificity for malaria cases in
this setting [21].
A schematic representation of the trial is shown in
Figure 2.Randomisation
In cluster-randomised controlled trials it is particularly
important to minimize imbalance for factors known to
be highly correlated with the disease outcome - in this
case age and location. In each cluster, children will be
enrolled with equal numbers of children aged 6 to 35
months and 36 to 60 months, and children who drop
out of the study in year 2 will be replaced, as far as pos-
sible, by children of a similar age. At each step of the
wedge, clusters will be selected, as far as possible, to
maintain an even balance of children in the 2 age
groups. Balanced randomization will be used to ensure
that, within each health centre catchment area, half of
village clusters will have PPF-LLIN and half LLINs by
the end of July 2014.
Stratified randomisation of village-cluster to the trial
arms, as outlined above, will reduce some imbalances
between these but, as only a relatively small number of
units can be randomized in such a cluster design, it is
important to assess baseline levels of malaria and known
confounders. Baseline data parasite rates and anaemia
collected from enrolled children in each cluster in May
2014 will be used to assess imbalances in malaria at the
village-cluster level.
Observer bias will be reduced where feasible. Both types
of nets will be of a similar shape and colour. As well as
using RDTs, blood films will be read by microscopists
blinded to the identity and intervention status of the sub-
jects. Mosquito collector bias will be reduced by using
standard Centers for Disease Control and Prevention
(CDC) miniature light traps, which do not rely on the abil-
ity of the fieldworker to collect specimens. Trap catches will
Figure 2 Schematic representation of the trial.
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they will be blinded to the trap location and intervention
status. The processes of the intervention, both for PPF-
LLIN and LLINs, will be monitored closely not only for
quality but also to document any bias between the clusters.
Interventions
Long-lasting insecticidal nets
The LLINs are manufactured by Sumitomo Chemical
(Japan). These are WHO recommended and meet WHOspecifications with 2% w/w permethrin incorporated into
polyethylene fibres giving adequate release of permethrin
for about 5 years. These nets will be distributed at the be-
ginning of the main transmission season, at no cost to the
recipients. We will use white ‘extra family’ size rectangular
nets (180 cm wide × 190 cm long × 150 cm high) of a white
colour throughout. Government Roll Back Malaria infor-
mation, education and communication procedures will be
followed to encourage correct net use and maintenance,
including supplying the nets in individual pre-opened bags.
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Banfora, under the control of a delegated individual,
ready to be moved to the Health Facilities in batches by
lorries and held by the officers in charge before being
transported to the villages for distribution by the study
team. In advance of distribution, the number of beds/
sleeping places and the number with LLINs will be
counted. New nets will be exchanged for old nets at the
household level to achieve one LLIN per bed/sleeping
place. Net use by study children will be monitored dur-
ing the monthly travel/residence surveys during the
2014 and 2015 transmission seasons.
Permethrin and pyriproxyfen long-lasting insecticidal nets
PPF-LLIN will be provided by Sumitomo Chemical
(Japan) and are currently undergoing evaluation by the
WHO Pesticide Evaluation Scheme. The nets contain 2%
w/w permethrin and 1% w/w pyriproxyfen incorporated
into polyethylene fibres giving adequate release of per-
methrin and pyriproxyfen for an estimated 3 years
(decay rates of the insecticides on PPF-LLIN are similar
to those of LLINs over 6 months, unpublished data).
The PPF-LLIN will be the same size and colour as the
LLINs and will be distributed the same way, but this dis-
tribution will be to the first 5 village clusters 1 month
after the LLIN distribution and will be rolled out in a
wedge-shaped design at monthly intervals during the
main transmission season in 2014 and 2015. PPF-LLIN
will be stored and distributed in a similar manner to the
control LLINs.
Clinical data collection and patient treatments
PCD for malaria will be maintained during the transmis-
sion seasons in 2014 and 2015 (June to December 2014,
and June to December 2015). Parents/guardians will be
encouraged to take their child to the health facility their
village is affiliated with at any time their child becomes
unwell. The cost of travel and treatment for sick chil-
dren will be met from the study funds. Study nurses will
work in close collaboration with the government health
workers to monitor malaria cases as indicated above.
Project fieldworkers will visit each nurse regularly, at
least once a week, to record children with malaria
episodes.
The end of transmission season survey in December
2015 will be the final study visit for the enrolled children
in the cohort and will be similar to the end transmission
season survey in 2014.
During the course of the study participants are free to
receive medication from health personnel outside the
study team but they are encouraged to use their allo-
cated health facility. During the clinical surveys, sick
children, those with anaemia (haemoglobin (Hb) <9 g/
dL), diagnosed malaria or any other mild illness will bereferred to their health facility. Children with severe
malaria, or other serious conditions, will be referred to
Banfora or Sideradougou Health Centres for treatment.
For safety considerations (see section below) we will
identify asthmatic residents in study villages by name,
household and village. During distribution and follow-up
of PPF-LLIN in 2014 and 2015 these residents will be
checked weekly by trial nurses for any aggravation of
their symptoms for the first month after net donation
and at the end of this month they will ask these resi-
dents to contact the study team if they have cause for
concern. We will also identify pregnant women in study
villages from antenatal clinic records, from June 2014
onwards, and outcomes of pregnancies will be recorded
onto data forms, including miscarriages, live/still birth,
weight and any recorded malformations. The regular
monthly demographic surveillance system (DSS) in trial
villages will also include reports of miscarriages. Data on
asthmatics and pregnancy outcomes will then be linked
to the date of reception of PPF-LLIN to examine if the
events are associated with PPF-LLIN.
Clinical evaluations
The main morbidity outcome will be incidence of clin-
ical disease assessed by PCD; data from this will provide
the primary endpoint of the study. Mild malaria and
parasitaemia is common in all children in this area of
highly seasonal malaria [21-23]. Study nurses in the 6
health facilities (Tiefora, Koflandé, Boussara Brousse,
Madiasso, Soukara II and Kangounadeni) within the
study area will document episodes of malaria in study
children who present directly to them. At the health fa-
cilities malaria diagnosis will rely on the use of RDT but,
in addition, thick blood films will be made for Giemsa
staining and later microscopy to estimate parasite dens-
ity. To facilitate documentation of all consultations by
study children, all enrolled children will be issued with
enumerated photo identity cards. The child’s study num-
ber, initials and village code will be recorded for all clin-
ical events on the case report form (CRF); to maintain
confidentiality the initials will not be entered into the
data set.
During the surveys all children enrolled in the cohort
who are present and the randomly selected children for
the cross-sectional surveys will be clinically examined
for obvious symptoms and signs of illness, temperature
will be measured with calibrated digital thermometers
and spleen enlargement will be measured by experienced
nurses using Hackett’s scoring system. All children will
be finger pricked for immediate measurement of
anaemia using a spectrophotometer (HaemoCue®,
Ängelholm, Sweden) and preparation of thick smears.
If a child reports with fever in the last 48 hours and/or
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for presence of parasites by RDT.
The primary endpoint selected is the definition of mal-
aria used commonly in West Africa in research studies
and in National Treatment Guidelines [24-26]. This end-
point does not include a measure of parasite density and
a parasite cut-off level may increase specificity. We thus
also intend to use the logistic regression method of
Smith and colleagues [26] to examine the effect of para-
site cut-off on the specificity and sensitivity of the defin-
ition of clinical malaria. This method has been endorsed
by a WHO study group for use in studies defining mal-
aria vaccine efficacy [21].
Entomological evaluations
Exposure to mosquitoes will be measured by surveil-
lance with light traps to obtain the primary entomo-
logical endpoint [27]. A CDC miniature light trap will be
positioned close to a single sleeper protected with a
LLIN or PPF-LLIN. Mosquitoes will be identified by mi-
croscopy and the numbers of An. gambiae s.l., An. funes-
tus and other anophelines recorded. The presence of
sporozoites in An. gambiae s.l. will be identified using an
enzyme-linked immunosorbent assay [28] and An.
gambiae s.l. females will be typed to species by PCR
[29]. In the case of An. gambiae s.s., S and M forms will
be identified by PCR [30]. Published kdr resistant
markers will be typed by PCR [31,32].
6 sentinel clusters will be selected for measurement of
the secondary entomological endpoints. Larvae will be
collected from a range of breeding sites within each of
these sites at the beginning and end of the transmission
season in each year of the study. The prevalence of re-
sistance to pyrethroids will be measured using standard
diagnostic dose assays with papers impregnated with
permethrin, obtained from WHO [33]. To quantify the
strength of resistance, a modification of the CDC bottle
bioassay will be used in which 3- to 5-day old non-
blood-fed female mosquitoes are introduced into 250
mL glass bottles pre-coated with a range of permethrin
concentrations. After a 1 hour exposure the mosquitoes
are transferred to a holding tube, provided with sugar
and water, and mortality recorded 24 hours later. The
concentration required to obtain 50% mortality, 24
hours post-exposure is recorded.
To assess the impact of PPF-LLIN on Anopheles gam-
biae egg production and the survival of the larvae that
emerge from these eggs, blood-fed mosquitoes will be
collected from inside houses via manual aspiration or
when exiting houses using exit traps. The female mos-
quitoes will be transported to the local insectary at
Banfora and the number of females that lay eggs, num-
ber of eggs hatching and survival to L2 larval stages will
be recorded. This will be performed in all 6 sentinelclusters at the beginning and end of the transmission
season in each year. In the first round of monitoring, all
houses will have standard LLINs and at the final round
of monitoring all will have PPF-LLIN.Study procedures and evaluations
LLIN distribution will be completed in mid-2014. Study
nurses and field assistants will be provided with re-
fresher training on diagnosis of malaria, the use of RDT
and study procedures in 2014 and 2015 before the trans-
mission season.
The compound of each study child will be geo-
referenced using a hand-held global positioning system,
as the primary data analysis has a spatial component.
Travel/residence of cohort children will be assessed at
monthly intervals on brief questionnaires to estimate
their time at risk, and their bed net usage will be
assessed at the same time.
Thick blood films will be stained with Giemsa and ex-
amined under 1000-fold magnification by trained, expe-
rienced microscopists. Parasite counts will be recorded
per high power field and 100 fields will be counted
before a slide is declared negative. Parasite density will
be estimated assuming that one parasite per high power
field equals 500 parasites/μL [34]. 2 slides will be pre-
pared from each subject and read separately by 2 experi-
enced microscopists; discrepancies in positive and
negative reads and those greater than 10-fold between
the 2 reads will be resolved by the microscopy super-
visor. Field staff will deliver all CRF to the study phys-
ician within 2 days of the clinical attack or survey date.
The study physician will check all CRFs weekly for
completion and data consistency.Safety considerations
Although adverse events (AEs) arising from either net
are highly unlikely, we will document their safety in a
community setting, by recording AEs and serious ad-
verse events (SAEs) in the study cohort and population
for the duration of the study. The trial will follow stand-
ard definitions for AE and SAE agreed by consensus of
the Collaborating Centres of the WHO International
Drug Monitoring Centre (Uppsala, Sweden). The occur-
rence of AEs will be sought by non-directive questioning
of the study children at monthly visits during the trial.
AEs will also be recorded if volunteered by study chil-
dren or their parent/carer or are noted by nurses
through physical examination, laboratory test, or other
assessments at any contact with the participant; these
will be recorded on the child’s CRF for that visit. All AEs
such as skin rashes, respiratory problems, streaming
eyes, and so forth, will be recorded with the grade of se-
verity (mild, moderate or severe).
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resident pregnant women, and asthma signs/symptoms
in pre-identified asthmatic residents, as indicated in the
clinical data collection and patient treatments above.
During the course of the study, SAEs will be captured
using a specific SAE report form and within 2 days of
the start of the SAE, field staff will deliver a completed
SAE report to the study physician. The study physician
will log these in a query book noting the child’s study
identification number or the residents demographic sur-
veillance system number and village of residence and re-
port these to the Principle Investigator who will inform
the responsible member of the trial Data and Safety
Monitoring Committee. Excessive grouping of SAEs by
clusters will be reported to the study’s Data Monitoring
and Ethics Committee and Trial Steering Committee.
Handling of drop-outs/withdrawals
If an individual wants to terminate his/her participation,
no further follow-up will be performed. There will be no
replacement during the surveillance period in either year
but in May 2015 children who have withdrawn, or are
no longer in the study for whatever reason, will be re-
placed by children resident in the same cluster and of
the same age group if informed consent is provided. If a
household withdraws consent, no further follow-up will
be made in that household. A child who was participat-
ing from that household will be replaced from within
the same cluster and age group and, if the house was
participating in the entomology collections, it will be re-
placed by a neighbouring house of the same type if pos-
sible. If a village opts out of the study before July in
either year replacement by a neighbouring village will be
considered.
Study endpoints
Clinical
Primary: incidence of clinical episodes of malaria pre-
senting at health facilities defined as a child with an axil-
lary temperature ≥37.5°C or a history of fever in the past
48 hours, together with the presence of P. falciparum
parasites of any density detected by RDT in the absence
of other detectable cause of fever.
Secondary: (i) mean Hb concentration in children in
the 2 study arms measured at the end of the transmis-
sion season survey; (ii) P. falciparum parasite rates in
children in the 2 study arms measured at the end of the
transmission season.
In addition we will also report
 the incidence of malaria defined by history of fever
or temperature ≥37.5 °C and a P. falciparum
parasitaemia cut-off to give optimum sensitivity and
specificity in this setting the number of children with enlarged spleens at the
end of each transmission season.Entomological
Transmission parameters in the 2 arms of the study will
be estimated from measurements made throughout the
2 transmission seasons.
Primary: the EIR for An. gambiae s.l. and An. funestus/
light trap/night inside sleeping rooms.
Secondary: (i) change in the prevalence (% mortality
using diagnostic dose) and strength (LC50 value) of re-
sistance to permethrin in each study arm throughout the
study; (ii) the fertility and fecundity of adult female An.
gambiae s.l. collected inside houses in both study arms.
Tertiary: (i) the relative abundance of different anoph-
eline species and forms in light traps collected in each
arm of the trial; (ii) the parity of An. gambiae to measure
mean population longevity.Sample size rationale
Clinical
LLINs reduce malaria morbidity by approximately 50%
[3]. The combined impact of using permethrin, a pyreth-
roid, and pyriproxyfen is unknown. If the effects were
simply additive a mean reduction of 75% could be antici-
pated for PPF-LLIN (that is, LLINs alone will reduce in-
cidence by 50%, and if we assume the pyriproxyfen alone
may reduce the remaining 50% incidence by half, there
would be a 75% reduction). However, the effects may be
synergistic (for example, by having a mass killing effect).
In order to change national guidelines on the use of
LLINs we consider that PPF-LLIN should be at least
25% more effective than LLINs. A study of 3- to 60-
month old children in Burkina Faso reported an inci-
dence of clinical episodes of malaria of 1.5 episodes/
child/year. Malaria incidence data for 2012 from villages
in the Banfora region of Burkina Faso indicate the coeffi-
cient of variation (CV) for this study will be approxi-
mately 0.25. Regarding this study as a simple cluster-
randomised controlled trial, assuming CV = 0.25 and
that an average of 50 children will be monitored in each
cluster for 2 seasons, the study will have 90% power to
detect a 25% increase in protection with PPF-LLIN com-
pared to LLINs (that is, a reduction in the incidence of
clinical episodes of malaria from 1.5 to 1.125 episodes/
child/year) at the 5% level of significance if there are
19.38 clusters in each arm [35]; we thus propose to re-
cruit 20 village clusters into each arm of the study.
Adjusting for a coefficient of up to 0.5 for the differences
in cluster size (the data from Banfora cited above sug-
gest that this CV will be much lower - approximately
15%), 20 clusters per study arm will still provide the
study with 85% power [36].
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[37], 20 clusters in each arm and CV = 0.3, the study
could detect a 30% reduction of prevalence, with 5% sig-
nificance and 80% power, between the study arms if lon-
gitudinal cohorts for each cluster contain at least 45
children. Assuming mean Hb around 10.5g/dL, 20 clus-
ters in each arm and CV = 0.1, the study could detect a
difference of 1.0g/dL in mean Hb, with 5% significance
and 80% power, between the study arms if at least 35
children were followed in each cluster .
Entomological
Based on a study using light traps in an adjacent study
area in Burkina Faso in 2010, we expect that the mean
number of female An. gambiae s.l. per trap/village will
be 45 during the rainy season (with a CV = 0.35). In
order to demonstrate a 33% reduction in blood-questing
indoor mosquitoes (that is, unfed An. gambiae) associ-
ated with PPF-LLIN, with 80% power and at the 5% level
of significance, would require 6 houses in each cluster
and 14 clusters in each arm of the trial over 2 years [35].
To allow for loss to follow-up due to people moving
house during the study period we propose to include at
least 6 houses in each cluster and 20 clusters in each
study arm for 2 years.
Data handling and record keeping
The demographic data will be recorded by fieldworkers
and the clinical data by study nurses on standardised
data forms. Each child in the cohort will be identified by
a unique identification number and non-cohort children
participating in the cross-sectional surveys will be identi-
fied by their demographic surveillance number. All
forms and datasets will identify participants by these
numbers, and names will not be entered.
After the collection and verification, data will be
moved to the data management unit in Banfora for data
entry. Data forms will be double entered (firstly by field
staff and then by data entry staff ) and the entries com-
bined and errors corrected to produce a single dataset.
This will be checked for consistency by generic and
study-specific algorithms designed to identify sources of
error. Inconsistencies will be checked against the ori-
ginal forms and errors will be corrected where possible,
for example by checking in the field, or put to missing,
to produce final datasets.
All forms with subject names and/or clinical data will be
kept in a cabinet and locked when not in use; the key will
be kept by the study coordinator or delegate. The elec-
tronic datasets will be password protected. Hard copies of
the data will be stored for 10 years. Clinical forms will be
kept separately from that containing personal identifica-
tion (for example, consent forms). The datasets will be
password protected and only accessed by authorized studystaff and the study data manager until after publication.
Data will be stored for at least 10 years.
Analytical plan
A per protocol and an intention to treat analysis will be
conducted.
Outcome 1 – malaria morbidity
The primary endpoint is a comparison of the incidence of
clinical episodes of malaria in children in the 2 interven-
tion groups, measured by PCD. After a case of malaria is
treated, time of observation will be censored for 3 weeks
and further attacks of malaria during this period are not
considered. History of travel away from the village for pe-
riods of over a week will be captured by the monthly sur-
veys and time at risk will be censored for such periods. In
addition, malaria cases in children who resided outside
their study village for more than half the elapsed study
period at the time of illness will be censored. An initial
analysis will compare the incidence rates between the 2
intervention groups, adjusted for duration of sleeping
under a PPF-LLIN. However, the main endpoint analysis
will also adjust for distance between village clusters with
different types of nets [38]. This adjustment is critical
since the impact of PPF-LLIN is likely to increase as they
cover larger areas and so reduce the spill over of mosqui-
toes from villages with LLINs. Specifically, a village with
PPF-LLIN surrounded by other villages with PPF-LLIN is
likely to be better protected against malaria than a village
with PPF-LLIN surrounded by villages with LLINs.
Since the replacement of drop-out individuals may
introduce bias we will repeat the primary analysis in-
cluding and excluding this group.
Each of the outcome measures collected in this study
will be analysed using multi-level statistical modelling
methods, with appropriate distributional assumptions
(for example, logistic, Poisson or negative binomial for
counts and rates, normal for biochemical measures, and
so forth). Within each model, effect size (that is, differ-
ence between PPF-LLIN and LLIN clusters) will, as ap-
propriate, be adjusted for clustering within the groups of
villages, the shortest distance between each PPF-LLIN
cluster of villages and its nearest control, LLIN, village-
cluster, the time of use of current nets (to account for
different times in PPF-LLIN and LLIN conditions for
each group of villages), village-cluster size, sex distribu-
tion, house design, bed net use, and other relevant po-
tential confounding factors. Effect sizes will be presented
as mean differences or rate differences/ratios as appro-
priate, with 95% confidence intervals.
Outcome 2 - malaria transmission
Differences in malaria transmission experienced in the 2
arms of the study will be estimated by comparing the
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length of time under PPF-LLIN and distance between
village clusters with the 2 different types of nets. Gen-
eralised estimating equations will be used to estimate
differences in numbers of indoor mosquitoes, adjusting
for repeated measures within clusters and possible
covariates.
Secondary endpoints
For the secondary clinical endpoints we will compare: (i)
mean Hb concentration in children at the end of the
transmission seasons; (ii) incidence of malaria defined by
history of fever or temperature ≥37.5 °C and a P. falcip-
arum parasitaemia cut-off defined to give optimum sen-
sitivity and specificity in this setting; (iii) parasite rates
(sexual and asexual) in children at the end of the trans-
mission seasons; (iv) number of children with enlarged
spleens at the end of the transmission seasons; and (v)
prevalence of anaemia (mild, moderate, severe). Anaemic
statuses will be defined as: severe anaemia = Hb <5 g/dL,
moderate anaemia = Hb range from 5 to <8 g/dL and
mild anaemia = Hb range from 8 to <11 g/dL.
In general, all quantitative outcomes will be compared
using appropriate summary statistics, such as mean dif-
ferences or risk ratios. Hypothesis testing will be based
on a 2-sample unpaired t test, adjusting for possible co-
variates. If the data do not satisfy normality and constant
variance assumptions, an appropriate non-parametric
test will be applied. Both linear regression (for continu-
ous variables such as Hb levels) and logistic regression
(for dichotomous variables such as presence or absence
of parasitaemia) will be used to quantify the group dif-
ferences allowing for individual level covariates (such as
age, house design, bed net use) using covariance struc-
tures that represent the appropriate level of clustering.
Ethical approval
This study is conducted in accordance with the princi-
ples set forth in the International Conference on
Harmonisation Harmonised Tripartite Guideline for
Good Clinical Practice and the Declaration of Helsinki
in its current version, whichever affords the greater pro-
tection to the participants. It was approved by the
Comité d’Ethique pour la Recherche en Santé on 8
October 2013 (ref: 2013-10-101), the Institutional review
board from Centre National de Recherche et de Formation
sur le Paludisme and by Durham University Biological and
Biomedical Sciences Devolved Ethics Sub-Committee on
17 January 2014.Discussion
The future of malaria vector control in sub-Saharan
Africa is threatened by the rapid rise of malaria vectorsresistant to pyrethroids [5], currently the only insecticide
class available for treating LLINs. Finding solutions to
the problem of insecticide resistance is therefore im-
mensely important to ensure that malaria control re-
mains effective. Here we assess whether PPF-LLIN,
which contain permethrin and pyriproxyfen, provide
additional protection against permethrin-resistant mal-
aria vectors compared with current best practice of
LLINs alone. The trial is designed to measure whether
the double intervention will provide greater protection
against clinical malaria in children by substantially
(>25%) reducing transmission.
This is the first clinical trial where a combination of
insecticides will be used on one bed net. Unusually the
net includes pyriproxyfen which is an insect growth
regulator. Unlike conventional insecticides such as per-
methrin, its main mode of action is not to kill mosqui-
toes, but to reduce their fertility and fecundity, once
they have blood-fed. We hypothesise that the impact of
this intervention will be greatest when a large number of
people/communities use this net over a wide area. In es-
sence we anticipate that the intervention will have a
community-wide impact, reducing the number of mos-
quitoes within a PPF-LLIN treated area. It is largely for
this reason that we have selected a novel study design
where this new net is rolled out in a step-wedge fashion
to the populations over a 2-year period. We expect that
as coverage increases those living in clusters with PPF-
LLIN surrounded by other clusters with PPF-LLIN will
be better protected against malaria vectors than those
on the fringes, where mosquitoes may spill-over from
areas without PPF-LLIN. Thus, in the analysis we will
consider both where and when people get malaria in
order to estimate the efficacy of PPF-LLIN.
The main outcome measure will be clinical malaria
incidence as measured by PCD which is considered to
generate information of more direct relevance to public
health than active case detection and is thus more suit-
able for evaluating population-level malaria interven-
tions [39]. It is particularly relevant as many African
countries, like Burkina Faso, have policies that malaria
should be eliminated as a public health problem. The
clinical outcomes will be measured in children aged 6
months to 5 years old as this age group experiences the
greatest burden of malaria in this country. The lower
limit of 6 months has been selected for cultural reasons
and since younger children have been shown to be less
likely to develop clinical malaria within their first 6
months of life [40-44].
This apparent protection has been linked to passive
transfer of anti-malaria antibodies by earlier experimen-
tal studies [44-46]. In addition to quantifying malaria
incidence and parasite rates, we will measure anaemia in
the community surveys, since malaria is a major risk for
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hookworm infection, are infrequent); thus, docu-
mented changes in anaemia will complement the main
outcomes.
There are no apparent risks to the safety of individuals
or communities in the use of the conventional nets.
Permethrin-treated long-lasting nets have been fully
evaluated by the WHO Pesticide Evaluation Scheme and
approved for vector control [6]. However, PPF-LLIN
have not previously been evaluated in the field before,
apart from small-scale experimental hut studies [11].
Whilst we do not anticipate any serious impacts of the
combination of permethrin and pyriproxyfen since the
safety profile of both these active compounds is deemed
acceptable by the WHO Pesticide Evaluation Scheme,
we cannot exclude the possibility that there might be
side effects when using the combination. For this reason
it is important to assess AEs and especially any SAEs in
study subjects during the course of the trial to determine
whether there is an excess of side effects associated with
the PPF-LLIN.
Study children will benefit from a health check at the
surveys and all participants will benefit from the health
facility clinical services which will be supported by train-
ing and the presence of study nurses in addition to gov-
ernment staff. It is also important that the correct
normal practice of parents/carers in the case of their
child becoming sick is not altered in a detrimental fash-
ion by their child being enrolled in the study. For ex-
ample a parent/carer may delay taking a child to the
nearest health facility/post if they think that a study
nurse is visiting their village the next day. Both the
provision of fares when a children reports sick at a
health facility and emphasis of the vital role of parent/
carers during enrolment and the conduct of the study
will help to mitigate against this.
The rapid spread of pyrethroid resistance in African
vectors is a cause of concern. Although we are currently
lacking direct evidence that this is interfering with mal-
aria control, it is likely that this will become an issue in
future. There is therefore an urgent need to find alterna-
tive strategies for dealing with insecticide resistance. A
net like PPF-LLIN that uses a combination of 2 different
classes of active ingredients represents a possible solu-
tion to the problem since it is less likely that vectors will
be resistant to both classes, especially since no cross re-
sistance has been reported for these 2 active ingredients.
The results of this trial will therefore be of interest to
those involved in malaria control in Burkina Faso and
other countries as an insecticide resistance management
strategy.
Trial status
Recruiting.Additional file
Additional file 1: Information sheet and consent form.
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